Anti-Viral Therapies Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

The global anti-viral therapies market is expected to grow from US$ 47,228.91 million in 2021 to US$  82,928.76 million in 2031; it is estimated to grow at a CAGR of 8.4% from 2022 to 2031.

Anti-viral therapies involve the development of a treatment for viral infections. There are several strategies used to develop anti-viral therapy, including direct-acting anti-virals that target viral proteins, enzymes, or nucleic acids; passive antibodies that neutralize circulating viruses; and drugs that target cellular proteins or processes essential for viral replication.

The anti-viral therapies market is attributed to the increasing R&D expenditures in pharmaceutical companies and rising government support for research activities and clinical trials. However, the high cost of drug development is hampering the growth of the market.

The anti-viral therapies market is segmented on the basis of type, application, mechanism of action, and geography. The report offers insights and in-depth analysis of the anti-viral therapies market, emphasizing various parameters such as market trends, technological advancements, and market dynamics, as well as the competitive landscape analysis of leading market players.

Market Insights

 

Increasing R&D Expenditures in Pharmaceutical Companies Bolsters Anti-Viral Therapies Market Growth

Research and development (R&D) is an essential part of a company’s business. Pharmaceutical companies focus on R&D to introduce new drugs with enhanced medical and commercial potential. These companies invest majorly in R&D activities with an aim to deliver high-quality and innovative products in the market.

R&D Investments by Major Pharmaceutical Companies

 

Note: Current conversion rate is considered.

Source: Annual Reports and The Insight Partners Analysis

R&D spending by the biopharmaceutical companies has increased over the years. According to the report of the Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expenditure of biopharmaceutical companies increased from US$ 49.6 billion in 2012 to US$ 58.8 billion in 2015. In the fiscal year 2014–2015, 16 pharmaceutical companies were among the world’s top 50 companies in terms of total R&D investment. Novartis, Roche, Johnson & Johnson, and Pfizer are among the top 10 leading R&D investing companies globally. Further, in 2021, Astellas Pharma invested US$ 1803.70 million in the R&D of new and advanced drugs. Thus, an increase in R&D expenditure is anticipated to drive the anti-viral therapies market during the forecast period.

Type-Based Insights

Based on type, the anti-viral therapies market is bifurcated into generic drugs and branded drugs. The branded drugs segment held a larger share of the market in 2021; however, the generic drugs segment is anticipated to register a higher CAGR during the forecast period.

 

Mechanism of Action-Based Insights

Based on mechanism of action, the anti-viral therapies market is segmented into nucleotide polymerase inhibitor, reverse transcriptase inhibitors, protease inhibitors, and others. The nucleotide polymerase inhibitor segment held the largest share of the market in 2021; also, the reverse transcriptase inhibitors segment is anticipated to register the highest CAGR in the market during the forecast period due to its effectiveness in reducing the spread of viral infections. Hence, the need and use of reverse transcriptase inhibitors are expected to increase in the coming years, which is likely to fuel the market growth across the globe.

Application-Based Insights

Based on application, the global anti-viral therapies market is segmented into HIV, hepatitis, herpes, virus influenza, and other applications. The HIV segment held the largest share of the market in 2021. Further, the hepatitis segment is estimated to register the highest CAGR during the forecast period.

By geography, the global market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

The Asia Pacific anti-viral therapies market is expected to grow at the fastest rate during the forecast period. The market is estimated to grow during the forecast period due to the rising pharmaceutical industry in China, Japan, India, and other Asia Pacific countries. The increasing incidences of viral diseases in the region and growing product developments by the local as well as international market players is likely to favor market growth. Further, China's pharmaceutical industry is among the largest pharmaceutical industry across the globe. The country has shown significant growth in active pharmaceutical ingredient manufacturing, competitiveness, innovations, and final dosage formation. Hence, most multinational companies are showing interest in the Chinese market for drug sales.

Growing efforts by governments of various countries and pharmaceutical and biotech companies to treat COVID-19 patients are likely to propel the growth of the anti-viral therapies market during the forecast period. In the US, the FDA has approved the emergency-use authorization of experimental drugs. Clinical trials of remdesivir, monoclonal antibodies, interferons, ACE inhibitors, and hydroxychloroquine have all been registered in the US. Furthermore, pharmaceutical companies in the country are making tremendous efforts to develop drugs and vaccines for the treatment of COVID-19 patients. In June 2021, scientists from the University of Oxford had been testing existing drugs as therapies for COVID-19 patients. Furthermore, The European Commission in July authorized remdesivir, making it the first approved drug for the treatment of COVID-19 in the European Union.

Company Profiles

A few of the major players operating in the anti-viral therapies market include AbbVie Inc.; Abbott; F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Gilead Sciences, Inc.; GlaxoSmithKline plc; and Aurobindo Pharma Limited.

Anti-Viral Therapies Report Scope